Blogger DrugMonkey says that when it comes to NIH grants, a little failure can be a good thing. NIH/CSR review panels seem to be fixated on preliminary data, DrugMonkey says, perhaps because the reviewers think part of their job is to separate the projects that will succeed from those that will fail. But what does it mean to fail?